| Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019 | 306 | 2019 |
| The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models V D'amato, R Rosa, C D'amato, L Formisano, R Marciano, L Nappi, ... British journal of cancer 110 (12), 2887-2895, 2014 | 98 | 2014 |
| Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers C Di Mauro, R Rosa, V D'Amato, P Ciciola, A Servetto, R Marciano, ... British journal of cancer 116 (11), 1425-1435, 2017 | 87 | 2017 |
| Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors CD Mauro, A Pesapane, L Formisano, R Rosa, V D’Amato, P Ciciola, ... Scientific reports 7 (1), 9388, 2017 | 80 | 2017 |
| FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer JZ Drago, L Formisano, D Juric, A Niemierko, A Servetto, SA Wander, ... Clinical Cancer Research 25 (21), 6443-6451, 2019 | 73 | 2019 |
| Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells C D’Amato, R Rosa, R Marciano, V D’Amato, L Formisano, L Nappi, ... British journal of cancer 111 (6), 1168-1179, 2014 | 62 | 2014 |
| c-Src and EGFR inhibition in molecular cancer therapy: what else can we improve? S Belli, D Esposito, A Servetto, A Pesapane, L Formisano, R Bianco Cancers 12 (6), 1489, 2020 | 61 | 2020 |
| Tumour microenvironment and immune evasion in EGFR addicted NSCLC: hurdles and possibilities A Santaniello, F Napolitano, A Servetto, P De Placido, N Silvestris, ... Cancers 11 (10), 1419, 2019 | 60 | 2019 |
| Role of FGFR3 in bladder cancer: Treatment landscape and future challenges CM Ascione, F Napolitano, D Esposito, A Servetto, S Belli, A Santaniello, ... Cancer Treatment Reviews 115, 102530, 2023 | 51 | 2023 |
| Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity AB Hanker, BP Brown, J Meiler, A Marín, HS Jayanthan, D Ye, CC Lin, ... Cancer cell 39 (8), 1099-1114. e8, 2021 | 51 | 2021 |
| Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers DR Sudhan, A Guerrero-Zotano, H Won, PG Ericsson, A Servetto, ... Cancer cell 37 (2), 183-199. e5, 2020 | 48 | 2020 |
| Neoadjuvant treatment in locally advanced pancreatic cancer (LAPC) patients with FOLFIRINOX or gemcitabine nabpaclitaxel: a single-center experience and a literature review F Napolitano, L Formisano, A Giardino, R Girelli, A Servetto, A Santaniello, ... Cancers 11 (7), 981, 2019 | 41 | 2019 |
| Mechanisms of resistance to mTOR inhibitors L Formisano, F Napolitano, R Rosa, V D’Amato, A Servetto, R Marciano, ... Critical reviews in oncology/hematology 147, 102886, 2020 | 40 | 2020 |
| Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status L Formisano, V D'Amato, A Servetto, S Brillante, L Raimondo, C Di Mauro, ... Oncotarget 6 (28), 26090, 2015 | 39 | 2015 |
| Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer A Servetto, R Kollipara, L Formisano, CC Lin, KM Lee, DR Sudhan, ... Clinical Cancer Research 27 (15), 4379-4396, 2021 | 38 | 2021 |
| Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer K Lee, AL Guerrero-Zotano, A Servetto, DR Sudhan, CC Lin, L Formisano, ... Nature communications 11 (1), 5488, 2020 | 38 | 2020 |
| ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors AL Guerrero-Zotano, TP Stricker, L Formisano, KE Hutchinson, DG Stover, ... Clinical Cancer Research 24 (11), 2517-2529, 2018 | 32 | 2018 |
| FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors A Servetto, L Formisano, CL Arteaga Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876 (2), 188595, 2021 | 20 | 2021 |
| Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer K Lee, CC Lin, A Servetto, J Bae, V Kandagatla, D Ye, GM Kim, ... Cancer immunology research 10 (7), 829-843, 2022 | 16 | 2022 |
| Everolimus induces Met inactivation by disrupting the FKBP12/Met complex L Raimondo, V D'Amato, A Servetto, R Rosa, R Marciano, L Formisano, ... Oncotarget 7 (26), 40073, 2016 | 16 | 2016 |
